Abstract
In the last 20 years, microRNAs (miRNAs) have become the most promising class of diagnostic and prognostic biomarkers for human cancer. From a therapeutic perspective, advances in the understanding of the molecular role of miRNAs in the pathological processes have significantly influenced the selection of new therapeutic modalities. Moreover, the intrinsic characteristics that confer stability to miRNAs in vitro, allow a longer molecular/structural resistance and activity in vivo. Preclinical models have consistently underlined the feasibility and efficacy of miRNA-based therapies, either alone or in combination with current targeted therapies. The appealing strength of such therapeutic option dwells in miRNAs’ ability to concurrently target multiple genes, frequently in the context of a specific network/pathway. This property allows miRNA-based therapy to be extremely efficient in regulating distinct biological processes relevant to normal and pathological cell homeostasis. The purpose of this review is to summarize the role of miRNAs in gastrointestinal carcinogenesis and their potential use as novel biomarkers and therapeutics.
Keywords: Biomarkers, gastrointestinal carcinogenesis, locked nucleic acid, miRNAs, noncoding RNA, therapeutics.
Current Drug Targets
Title:MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis
Volume: 16 Issue: 4
Author(s): Edoardo D'Angelo, Caterina Vicentini, Marco Agostini, Andras Kiss, Raffaele Baffa, Aldo Scarpa and Matteo Fassan
Affiliation:
Keywords: Biomarkers, gastrointestinal carcinogenesis, locked nucleic acid, miRNAs, noncoding RNA, therapeutics.
Abstract: In the last 20 years, microRNAs (miRNAs) have become the most promising class of diagnostic and prognostic biomarkers for human cancer. From a therapeutic perspective, advances in the understanding of the molecular role of miRNAs in the pathological processes have significantly influenced the selection of new therapeutic modalities. Moreover, the intrinsic characteristics that confer stability to miRNAs in vitro, allow a longer molecular/structural resistance and activity in vivo. Preclinical models have consistently underlined the feasibility and efficacy of miRNA-based therapies, either alone or in combination with current targeted therapies. The appealing strength of such therapeutic option dwells in miRNAs’ ability to concurrently target multiple genes, frequently in the context of a specific network/pathway. This property allows miRNA-based therapy to be extremely efficient in regulating distinct biological processes relevant to normal and pathological cell homeostasis. The purpose of this review is to summarize the role of miRNAs in gastrointestinal carcinogenesis and their potential use as novel biomarkers and therapeutics.
Export Options
About this article
Cite this article as:
D'Angelo Edoardo, Vicentini Caterina, Agostini Marco, Kiss Andras, Baffa Raffaele, Scarpa Aldo and Fassan Matteo, MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis, Current Drug Targets 2015; 16 (4) . https://dx.doi.org/10.2174/1389450116666141210091454
DOI https://dx.doi.org/10.2174/1389450116666141210091454 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Assessment of Airway Inflammation by Exhaled Breath Condensate and Impedance Due to Gastroesophageal Reflux Disease (GERD)
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Implications of mTOR Inhibitors in the Treatment of Gastric Cancer
Current Cancer Drug Targets Regulation and Function of DNA and Histone Methylations
Current Pharmaceutical Design Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets Unique Applications of Novel Antifungal Drug Combinations
Anti-Infective Agents in Medicinal Chemistry Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews The Thyroid Gland: A Crossroad in Inflammation-Induced Carcinoma? An Ongoing Debate with New Therapeutic Potential.
Current Medicinal Chemistry 31P NMR Spectroscopy of Phospholipids: From Micelles to Membranes
Current Analytical Chemistry Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Current Cancer Drug Targets Zenker Diverticulum: A Potential Pitfall in Thyroid Ultrasound Evaluation: A Case Report and Systematic Review of Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipids as a Target for Drugs Modulating Multidrug Resistance of Cancer Cells
Current Drug Targets CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer Therapy
Current Medicinal Chemistry Immunonutrition in Surgical Patients
Current Drug Targets iPSCs Derived from Malignant Tumor Cells: Potential Application for Cancer Research
Current Stem Cell Research & Therapy Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target
Current Pharmaceutical Design Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects
Current Radiopharmaceuticals